Prostate cancer (PCa) is globally the second most diagnosed cancer type and the most
common cause of cancer-related deaths in men. Family history of PCa, hereditary breast …

Cancer is a leading cause of death worldwide, with an increasing mortality rate over the past
years. The early detection of cancer contributes to early diagnosis and subsequent …

In the United States, prostate cancer (CaP) remains the second leading cause of cancer
deaths in men. CaP is predominantly indolent at diagnosis, with a small fraction (25–30%) …

Results Limited specificity of the prostate-specific antigen (PSA) test brings a need to
develop new and better diagnostic tools. In the last few years, new approaches for providing …

Metastatic prostate cancer is associated with considerable morbidity and mortality. Standard
treatment for non-metastatic prostate cancer, to prevent metastatic progression, is androgen …

Oncobiomarkers act as perfect indicators for cancer detection. The latest advances in the
field of early stage diagnosis of cancer reveal that sensitive and selective measurement of …

Cancer, a common malignant disease, is one of the predominant causes of diseases that
lead to death. Additionally, cancer is often detected in advanced stages and cannot be …

Advanced prostate cancers that progress to tumor metastases are often considered
incurable or difficult to treat. The etiology of prostate cancers is multi-factorial. Among other …

Background Novel non-invasive biomarkers are urgently required to improve the diagnostic
sensitivity and specificity of prostate cancer (PCa). Therefore, the diagnostic value of …

Prostate cancer is one of the most frequently diagnosed male malignancies and can be
detected by prostate-specific antigen (PSA) as a biomarker. To detect PSA, several studies …